ReviewEuropean journal of obstetrics & gynecology and reproductive biology: X2025
Focused ultrasound treatment of cervical human papillomavirus infection and squamous intraepithelial lesions: A narrative review.
Review in European journal of obstetrics & gynecology and reproductive biology: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focused ultrasound (FUS) appears to be a promising form of thermal ablation for treatment of cervical lesions, but evidence supporting its use is limited. This review evaluated the efficacy and safety of FUS treatment of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL). The overall efficacy of FUS on HPV clearance was 75.0-85.7 % at 3 months, 35.5-77.1 % at 6 months and 64.7-94.1 % at 12 months. Its efficacy on low grade SIL and high grade SIL regression were 83.3-96.8 % and 70.9-96.6 % at 6 months, respectively. Complications were uncommon. FUS appears to be an effective and safe treatment modality for cervical HPV and SIL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.